Sponsor: Janssen PI: KWD Phase: 3
A Multicenter, Randomized, Double-Blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis: CNTO1959PSO3009
May 2017- Present
Sponsor: Novartis PI: KWD Phase: 4
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis (ADIPSO): CAIN457AUS07
April 2017- Present
Sponsor: Pfizer PI: SAF Phase: 2A
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis. B7931004
March 2017- Present
Sponsor: Bristol-Myers Squibb PI: KWD Phase: 2
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis. BMS IM011011
March 2017- August 2017
Sponsor:AbbVie PI: SAF Phase: 3
A Multicenter, Open-Label Study to assess the safety and efficacy of rIsankizuMab for maintenance in moderate to severe plaque type psoriasis. M15-997
March 2017- Present
Sponsor:Janssen PI: KWD Phase: 3
A Phase III Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects >/= 6 to < 12 Years of Age. CNTO1275PSO3013
January 2017- October 2017
Sponsor: UCB BioPharma PI: SAF Phase: 2B
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmocodynamics of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis. PS0010
October 2016- June 2017
Sponsor: Eli Lilly PI: SAF Phase: 1
A Multi-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients with Neutrophilic Skin Diseases. I7P-MC-DSAB
September 2016-Present
Sponsor: Kadmon PI: SAF Phase: 2
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Efficacy of KD025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy. KD025-211
September 2016-Present
Sponsor: Novartis PI: KWD Phase 3
A 52-week, Multicenter, Randomized, Double-Blind Study of secukinumab (300 mg) to demonstrate the efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis. CAIN457A2326
August 2016- Present
Sponsor: Evidera/Eli Lilly and Company PI: SAF Phase: 4
Assessment of the Content Validity of the Psoriasis Symptoms Scale (PSS). – EVA-18225-01
June 2016- Present
Sponsor: Eli Lilly PI: SAF Phase: 3
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients with Moderate-to-Severe Genital Psoriasis. – I1F-MC-RHBQ(1)
April 2016- Present
Sponsor: Boehringer Ingelheim PI: SAF Phase:
BI 655066 versus Ustekinumab and placebo comparators in a Randomized Double-Blind Trial for Maintenance use in Moderate to severe plaque type psoriasis-2 (U1tIMMa-2) – 1311.28
March 2016 – November 2017
Sponsor: Evidera/Eli Lilly and Company PI: SAF Phase: 4
Cognitive Interviewing of the Subcutaneous Administration Assessment Questionnaire (SQAAQ) in Patients with Moderate to Severe Plaque Psoriasis – EVA-18225
February 2016 – June 2016
Sponsor: Promius Pharma, LLC PI: KWD Phase: 3
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days – DFD06-CD-005
November 2015 to September 2016
Sponsor: Baxalta US, Inc./Baxalta Innovations GmbH PI: SAF Phase:3
A Phase III Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects with Moderate to Severe Chronic Plaque-type Psoriasis – 911401
October 2015 to October 2017
Sponsor: Eli Lilly and Company PI:SAF Phase: 3
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis – I1F-MC-RHBP
August 2015 to June 2017
Sponsor: Corrona, LLC PI:SAF Phase: 1
Corrona Psoriasis Registry – Corrona PSO-500
July 2015 to Present
Sponsor: UCB Biopharma, SPRL / Dermira, Inc. PI: SAF Phase: 3
A Phase III, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-and-Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects with Moderate to Severe Chronic Plaque Psoriasis – PSO003
May 2015 to Present
Sponsor: Amgen, Inc. PI: KWD Phase: 1
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis who Achieve Complete Clearance on Biologics – 20120363
May 2015 to April 2017
Sponsor: TOLMAR, Inc. PI:SAF Phase: 3
A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing TOLMAR Calcipotriene Ointment, 0.005% to Reference Listed Drug in the Treatment of Plaque Psoriasis – TOL2707A
March 2015 to June 2016
Sponsor: Amgen, Inc. PI: SAF Phase: 4
A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis. Phase 4 Study – 20101177
February 2015 to March 2016
Sponsor: Pfizer, Inc. PI: Phase: 2
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of PF-04965842 in Subjects with Moderate to Severe Psoriasis – B7451005
November 2014 to September 2015
Sponsor: Janssen Research and Development, LLC PI: SAF Phase: 2
A Phase II Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects with Moderate to Severe Plaque type Psoriasis – 38518168PSO2001
November 2014 to January 2016
Sponsor: Janssen Research and Development, LLC PI: SAF Phase: 3
A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis and Inadequate Response to Ustekinumab – CNTO1959PSO3003
November 2014 to July 2016
Sponsor: Janssen Research and Development, LLC PI: SAF Phase: 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis Incorporating Randomized Withdrawal and Retreatment – CNTO1959PSO3002
November 2014 to Present
Sponsor: Novartis Institutes for BioMedical PI: Phase:
A Randomized, Double-Blind, Placebo and Positive Controlled, Single and Multiple Dose Study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients – CCJM112X2101
November 2014 to January 2016
Sponsor: Hexal AG/Sandoz, Inc. PI: SAF Phase: 3
A Randomized, Double-Blind, Multicenter Study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira® in patients with moderate to severe chronic plaque-type psoriasis – GP17-301
July 2014 to July 2016
Sponsor: Amgen, Inc. PI: Phase:
A Study to Assess the Clinical Meaningfulness and Interpretability of Improvement in patient-reported psoriasis symptom severity over the course of treatment for chronic plaque psoriasis – 20130126 (HRA 1603A)
May 2014 to February 2016
Sponsor: AbGenomics PI: Phase:2
Efficacy, safety, tolerability, and pharmacokinetics of multiple doses of AbGn-168H administered by intravenous infusion to patients with moderate to severe chronic plaque psoriasis (randomized, double-blind, placebo-controlled) – 2014.002.01
May 2014 to April 2015
Sponsor: Novartis Pharmaceuticals PI: SAF Phase: 3
A 52-week, Multicenter, Randomized, Double-Blind Study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis – CAIN457A2317
May 2014 to November 2016
Sponsor: Janssen Research and Development PI: Phase: 1
Exploratory Genetic Study in Subjects with Moderate to Severe Psoriasis – NOCOMPOUNDPSO0001
March 2014 to September 2014
Sponsor: Amgen, Inc. PI: Phase:
A Comparison of Psoriasis Symptom Severity and Health-Related Quality of Life in Patients With Clear and Almost Clear Levels of Skin Improvement – 20130127 (HRA 1889A)
October 2013 to August 2014
Sponsor: Novartis Pharmaceuticals PI: KWD Phase: 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 80 weeks in subjects with moderate to severe nail psoriasis – CAIN457A2313
September 2013 to April 2017
Sponsor: Novartis Pharmaceuticals PI: KWD Phase: 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 80 weeks in subjects with moderate to severe palmoplantar psoriasis – CAIN457A2312
September 2013 to April 2017
Sponsor: Maruho North American, Inc. PI: Phase: 3
A Randomized, Vehicle-Controlled, Double-Blind, Parallel Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects with Plaque Psoriasis – M518101-US02
August 2013 to September 2015
Sponsor: AbGenomics BV PI: Phase:
Efficacy, safety, tolerability, and pharmacokinetics of multiple doses of AbGn-168H administered by intravenous infusion to patients with moderate to severe chronic plaque psoriasis (randomized, double-blind, placebo-controlled) – 2012.005.01
May 2013 to April 2014
Sponsor: Eli Lilly and Company PI: Phase:3
Pharmacokinetic Evaluations of Ixekizumab following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients with Moderate-to-Severe Plaque Psoriasis – I1F-MC-RHBL
April 2013 to October 2013
Sponsor: Eli Lilly and Company PI: SAF Phase: 3
A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period – I1F-MC-RHBC
February 2013 to Present
Sponsor: Merck Sharp & Dohme Corp. PI:SAF Phase: 3
A 64-Week, Phase III, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis – MK-3222-010
January 2013 to Present
Sponsor: Novartis Pharmaceuticals PI: SAF Phase: 3
A Multicenter, Double-Blind and Open Label, 4-year Extension Study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen – CAIN457A2304E1
November 2012 to October 2017
Sponsor: Novartis Pharmaceuticals PI: SAF Phase: 3
A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 4 years in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab – CAIN457A2302E1
October 2012 to November 2017
Sponsor: Celgene Corporation PI: SAF Phase:3B
A Phase IIIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, in Subjects with Moderate to Severe Plaque Psoriasis – CC-10004-PSOR-010
September 2012 to July 2015
Sponsor: Novartis Translational Sciences PI: Phase: 2
Phase II Randomized Double Blinded Placebo-Controlled, Multiple-Dose regimen study to assess the rate of histological clearance and effect on molecular pathways as well as on biomarkers of 12 months secukinumab 300 mg s.c. treated patients with chronic plaque-type psoriasis – CAIN457A2223
August 2012 to May 2015
Sponsor: Amgen, Inc. PI: Phase: 3
Phase III Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3 – 20120104
August 2012 to December 2015
Sponsor: Leo Pharmaceuticals PI: Phase: 2
A Phase II Study comparing treatment with LEP 90100 with betamethasone dipropionate in LEO 90100 vehicle and calcipotriol in LEO 90100 vehicle in subjects with psoriasis vulgaris – LEO 90100-7
May 2012 to December 2012
Sponsor: Leo Pharmaceuticals PI: Phase: 2
A Phase II Study comparing treatment with LEO 90100 with calcipotriol plus betamethasone ointment, LEO 90100 vehicle and ointment vehicle in subjects with psoriasis vulgaris – LEO 90100-35
May 2012 to November 2012
Sponsor: Stiefel Laboratories, Inc. PI: KWD Phase: 1
A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005%, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) with Plaque Psoriasis – STF 115750
March 2012 to August 2017
Sponsor: Eli Lilly and Co., Inc. PI:SAF Phase: 3
A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safey of LY2439821 in Patients with Moderate-to-Severe Plaque Psoriasis – I1F-MC-RHAZ
February 2012 to Present
Sponsor: Janssen Research and Development, Inc. PI: Phase: 2
A Phase II Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis – CNTO1959PSO2001
January 2012 to November 2013
Sponsor: Novartis PI: Phase: 3
A Randomized, Double-Blind, Multicenter Study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen. (SCULPTURE) – CAIN 457A2304
October 2011 to September 2013
Sponsor: Novartis PI: Phase: 3
A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Multicenter Study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanercept, and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis. (FIXTURE) – CAIN457A2303
September 2011 to October 2013
Sponsor: Pfizer PI: KWD Phase: 3
A Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy And Safety Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis – A3921078/A3921061
April 2011 to October 2016
Sponsor: Maruho PI: Phase: 2B
A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Center Phase IIb dose finding study of M518101 in plaque psoriasis patients – M518101-US01
March 2011 to March 2012
Sponsor: Schering-Plough/Merck PI: Phase: 2
A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis -P05495
December 2010 to January 2013
Sponsor: LEO Pharma PI: Phase:
Calcipotriol plus betamethasone dipropionate topical suspension compared to betamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle and the topical suspension vehicle alone in psoriasis vulgaris – LEO 80185-G23
September 2010 to July 2011
Sponsor: Celgene Corporation PI:SAF Phase: 3
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy And Safety Study Of Apremilast (CC-10004) In Subjects With Moderate To Severe Plaque Psoriasis – CC-1004-PSOR-008
August 2010 to October 2016
Sponsor: Wyeth PI: Phase: 1
A Phase I, Single Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of ILV-095 Administered Subcutaneously to Subjects With Psoriasis – 3226K1-1002-WW
April 2010 to September 2011
Sponsor: Amgen PI: Phase: 3
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis – 20070559
February 2010 to February 2011
Sponsor: Astellas Pharma Inc. PI: Phase:
Assessment and Tracking of Long-term Alefacept (LFA-3IgG1 Fusion Protein) Safety (ATLAS)
August 2009 to September 2012
Sponsor: Celgene Corporation PI: Phase: 2B
A Phase IIb, Multicenter, Treatment-Arm Blind, Safety And Efficacy 32-Week Extension Study Of Apremilast (CC-10004) In Subjects Who Completed The Treatment Phase Of The Core Study CC-10004-PSOR-005 – CC-10004-PSO-005E
April 2009 to December 2010
Sponsor: Eli Lilly and Company PI: Phase: 1
A Phase I, LY2439821 (Anti-IL-17 Humanized Antibody) Multiple-Dose Safety and Tolerability Study in Subjects with Psoriasis Vulgaris – I1F-MC-RHAG
January 2009 to June 2010
Sponsor: Abbott Laboratories PI: Phase:
A 10-Year, Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients with Chronic Plaque Psoriasis (ESPRIT) – P10-023
November 2008 to Present
Sponsor: Celgene Corporation PI: Phase: 2B
A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque-Type Psoriasis – CC-10004-PSO-005
October 2008 to January 2010
Sponsor: Novo Nordisk PI: Phase: 1
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Trial of Anti-IL-20 (109-0012) 100 mg/vial in psoriatic subjects, followed by an expansion phase – NN8226-1848
October 2008 to January 2011
Sponsor: Genzyme Corporation PI: Phase:
A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in the Treatment of Subjects with Moderate to Severe Chronic Plaque Psoriasis – HECTPSO2507
August 2008 to 2009
Sponsor: Centocor, Inc. PI: Phase:
A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics (PSOLAR) – C0168Z03
May 2008 to Present
Sponsor: Abbott Laboratories PI: Phase: 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis – M10-114
March 2008 to 2009
Sponsor: Abbott Laboratories PI: Phase: 3
A Phase III Multicenter, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who completed a Preceding Psoriasis Study with ABT-874 – M10-016
March 2008 to March 2012
Sponsor: Genentech, Inc. PI: Phase: 4
A Phase IV Randomized, Double-Blind, Placebo Controlled Study To Evaluate the Safety and Efficacy of XXXXX in Adult Patients with Moderate to Severe Plaque Psoriasis with Involvement of the Scalp.
March 2008 to 2009
Sponsor: Abbott Laboratories PI: Phase: 3
Open-label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy.
November 2007 to November 2009
Sponsor: Abbott Laboratories PI: Phase: 3
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis.
October 2007 to October 2009
Sponsor: Wyeth PI: Phase: 1
A Phase I, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of ILV-094 Administered Subcutaneously or Intravenously to Subjects With Psoriasis
October 2007 to June 2010
Sponsor: Centocor, Inc. PI: Phase: 3
A Phase III, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis. (T12)
March 2007 to October 2009
Sponsor: Amgen, Inc. PI: Phase:
Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis. (OBSERVE)
July 2006 to Present
Sponsor: Genentech, Inc. PI: Phase: 4
A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Efalizumab in Adult Subjects with Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
July 2006 to August 2007
Sponsor: Galderma Laboratories, L.P. PI: Phase: 4
A Phase IV, Open-Label Multicenter Community-Based 4-Wk Trial to Assess Efficacy, Tolerance to Tx & Patient Satisfaction w/ CLOBEX® Spray When Used as Mono- or Add-on Therapy to Existing Systemic/Topical Agents for Tx of Plaque Psoriasis
February 2006 to June 2006
Sponsor: Centocor, Inc. PI: Phase: 3
A Phase III Trial Evaluating the Efficacy and Safety of CNTO1275 in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis. (T09)
January 2006 to December 2011
Sponsor: Genentech, Inc. PI: Phase: 4
A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients with Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet
January 2006 to April 2007
Sponsor: Centocor, Inc. PI: Phase: 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-type to Severe Plaque-type Psoriasis (T08)
January 2006 to July 2011
Sponsor: Abbott Laboratories PI: Phase: 2
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Subcutaneous Injections of ABT-874 vs. Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis.
December 2005 to September 2008
Sponsor: Astellas Pharma US, Inc. PI: Phase: 3
A Phase III, Long-Term, Open Label Study to Evaluate the Safety of Twice-Daily Tacrolimus Cream-B in the Treatment of Psoriasis
September 2005 to April 2007
Sponsor: Genentech, Inc. PI: Phase:
Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events (RESPONSE) in Patients with Chronic Moderate to Severe Plaque Psoriasis.
April 2004 to November 2009
Sponsor: Abbott Laboratories PI: Phase: 3
A Phase III, Multicenter Study of the Efficacy and Safety of Long-Term Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis.
October 2004 to December 2005
Sponsor: Centocor, Inc. PI: Phase: 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Subjects with Plaque-type Psoriasis
February 2004 to June 2005
Sponsor: Amgen, Inc. PI: Phase: 4
A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects with Psoriasis
March 2004 to November 2004
Sponsor: Fujisawa Healthcare, Inc. PI: Phase: 3
A Phase III, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Once Daily 0.3% FK506 Gel versus Gel Vehicle in the Treatment of Psoriasis
March 2004 to November 2004
Sponsor: Centocor, Inc. PI: Phase: 2
A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dosing Regimens with Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects with Moderate to Severe Psoriasis
November 2003 to June 2005
Sponsor: Genentech, Inc. PI: Phase: 4
An Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults with Plaque Psoriasis Previously Enrolled in Study ACD2600g.
September 2002 to March 2004
Sponsor: Genentech, Inc. PI: Phase: 3B
A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults with Moderate to Severe Plaque Psoriasis Who Are Candidated for Systemic Therapy.
September 2002 to January 2003